Acetylsalicylic Acid
Extensive-Stage Small Cell Lung Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Extensive-Stage Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Bristol-Myers Squibb | Phase 3 | B |
Sacituzumab Tirumotecan Sichuan University | Phase 2 | B |
Palifosfamide-Tris Alaunos Therapeutics | Phase 3 | B |
Fludarabine National Cancer Institute (NCI) | Phase 1 | CC |
Syha1807 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | CC |
Egfr/B7H3 Car-T National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Acetylsalicylic Acid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →